Korea Investment CORP cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 23.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 27,163 shares of the life sciences company’s stock after selling 8,500 shares during the quarter. Korea Investment CORP’s holdings in Illumina were worth $5,411,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ILMN. First Citizens Bank & Trust Co. increased its holdings in shares of Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 12 shares during the period. Puzo Michael J increased its holdings in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after purchasing an additional 25 shares during the period. Flagship Harbor Advisors LLC increased its holdings in shares of Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after purchasing an additional 35 shares during the period. Eqis Capital Management Inc. increased its holdings in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after purchasing an additional 38 shares during the period. Finally, Broderick Brian C increased its holdings in shares of Illumina by 0.3% in the second quarter. Broderick Brian C now owns 13,152 shares of the life sciences company’s stock valued at $2,282,000 after purchasing an additional 40 shares during the period. Institutional investors own 93.04% of the company’s stock.

A number of brokerages have recently weighed in on ILMN. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup Inc increased their price objective on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays PLC increased their price objective on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation increased their price objective on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reissued a “market perform” rating and issued a $205.00 price objective (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and a consensus target price of $200.88.

TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Shares Sold by Korea Investment CORP” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/illumina-inc-ilmn-shares-sold-by-korea-investment-corp/1677718.html.

In other news, SVP Oene Mark Van sold 9,729 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total value of $2,056,029.57. Following the transaction, the senior vice president now owns 24,908 shares in the company, valued at $5,263,807.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. In the last 90 days, insiders sold 168,026 shares of company stock worth $34,234,070. Company insiders own 1.60% of the company’s stock.

Illumina, Inc. (NASDAQ ILMN) opened at $213.99 on Friday. The stock has a market cap of $30.49 billion, a price-to-earnings ratio of 61.06, a P/E/G ratio of 3.45 and a beta of 0.74. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.97 earnings per share. analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.